Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preladenant long-term extension study in moderate to severe Parkinson's disease
NL-OMON38067Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of preladenant in Parkinson's disease (PD), sponsored by Merck & Co. Started Feb 2012; status: active, not recruiting.
02
Drugs
preladenant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON38067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38067.